Biomerica signs exclusive distribution agreement in China for its colorectal screening test with total minimum purchase requirement of $17 million over 7 years and an upfront pre-payment of $1 million. MaxHealth to distribute Biomerica’s colorectal screening test to help identify… Read More
News
3rd Quarter Financials 2019 — April 16, 2019
IRVINE, California, — April 16, 2019 — Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $4,034,822 for the nine months ending February 28, 2019, compared to $4,433,785 for the period ended February 28, 2018. Sales for the three months… Read More
Biomerica Announces Notice of Allowance
Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS) Please Click Here for Press Release Safe Harbor Statement
Biomerica Announces Updates – HP Clinical Studies
IRVINE, CA –(February 4, 2019) — Biomerica Inc. (NASDAQ: BMRA) announced today regulatory and clinical advancements in its development program for its H. pylori diagnostic product. Based on recent discussions between Biomerica and the United States Food and Drug Administration… Read More
2nd Quarter 2019 Financials — January 15, 2019
Irvine, Calif. — January 15, 2019 — Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $1,500,791 for the three months ended November 30, 2018, compared to $1,613,636 for the same period in the previous year. Net sales were $2,773,661 for… Read More